Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

U.S. pharmacies strike first deals with counties over opioids

Published 07/13/2021, 12:47 PM
Updated 07/13/2021, 12:51 PM
© Reuters. FILE PHOTO: A Walgreens store is seen in Chicago, Illinois, U.S. February 11, 2021.  REUTERS/Eileen T. Meslar

By Brendan Pierson

NEW YORK (Reuters) - Pharmacy operators Walgreens Boots Alliance (NASDAQ:WBA) Inc, CVS Health Corp (NYSE:CVS), Rite Aid (NYSE:RAD) Corp and Walmart (NYSE:WMT) Inc have agreed to pay a combined $26 million to settle claims by two New York counties that they fueled an opioid addiction epidemic.

The settlements are the first reached by pharmacies in the ongoing nationwide litigation over opioids. The pharmacies did not admit wrongdoing.

Suffolk County's legislature approved the deals on Monday, while Nassau County's legislature is expected to vote on final approval next month.

The U.S. Centers for Disease Control and Prevention has said nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019. More than 3,000 lawsuits have been filed in the United States against drugmakers, distributors and pharmacies over the opioid epidemic.

Plaintiffs have accused drugmakers of falsely marketing opioids as safe, and distributors and pharmacies of ignoring red flags that they were being diverted to illegal channels. The defendants have denied the allegations.

CVS spokesman Mike DeAngelis said in an email that the settlement "reflects our position that opioid prescriptions are written by doctors, not pharmacists, and that opioid medications are made and marketed by manufacturers, not pharmacies."

The other pharmacies did not immediately respond to requests for comment.

The pharmacies settled the lawsuits last month shortly before they were to go to trial, though the agreements were not publicly disclosed at the time. Trial is now underway over the counties' and New York state's claims against the remaining defendants, a group of drugmakers and distributors.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Johnson & Johnson (NYSE:JNJ) also settled before trial for $263 million.

The funds will be used for mental health and addiction programs, representatives of the counties said.

"While these settlements cannot repair the damage done or bring back those who we lost to the grips of this epidemic, it has already made a substantial impact," Suffolk Legislator Rob Calarco said in a statement.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.